Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Degryse, S; de Bock, C E; Demeyer, S; Govaerts, I; Bornschein, S; Verbeke, D; Jacobs, K; Binos, S; Skerrett-Byrne, D A; Murray, H C; Verrills, N M; Van Vlierberghe, P; Cools, J; Dun, M D

Degryse, S; de Bock, C E; Demeyer, S; Govaerts, I; Bornschein, S; Verbeke, D; Jacobs, K; Binos, S; Skerrett-Byrne, D A; Murray, H C; Verrills, N M; Van Vlierberghe, P; Cools, J; Dun, M D.

Affiliation

Degryse S; VIB Center for Cancer Biology, Leuven, Belgium.
de Bock CE; KU Leuven Center for Human Genetics, Leuven, Belgium.
Demeyer S; VIB Center for Cancer Biology, Leuven, Belgium.
Govaerts I; KU Leuven Center for Human Genetics, Leuven, Belgium.
Bornschein S; VIB Center for Cancer Biology, Leuven, Belgium.
Verbeke D; KU Leuven Center for Human Genetics, Leuven, Belgium.
Jacobs K; VIB Center for Cancer Biology, Leuven, Belgium.
Binos S; KU Leuven Center for Human Genetics, Leuven, Belgium.
Skerrett-Byrne DA; VIB Center for Cancer Biology, Leuven, Belgium.
Murray HC; KU Leuven Center for Human Genetics, Leuven, Belgium.
Verrills NM; VIB Center for Cancer Biology, Leuven, Belgium.
Van Vlierberghe P; KU Leuven Center for Human Genetics, Leuven, Belgium.
Cools J; VIB Center for Cancer Biology, Leuven, Belgium.
Dun MD; KU Leuven Center for Human Genetics, Leuven, Belgium.

Leukemia ; 32(3): 788-800, 2018 03.

Article in En | MEDLINE | ID: mdl-28852199

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2018 Document type: Article Affiliation country: Belgium

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google